Page Title
Clinical Trial Finder
Observational Enrolling
A study of strength and muscle development to assess nutrition and lung function in people with CF ages 18 and older. (STRONG-CF)
This observational study will look at physical measurements, including body mass index and body composition, and compare them to bone density scans. This study includes measurements of arm circumference, hand-grip strength, distance walked in 6 minutes, and lung function.
The results of this study will provide information about the nutrition and body composition of people living with CF. This study will also help researchers understand better what contributes to malnutrition in some adults with advanced lung disease. This information will provide a baseline - or starting point - for future studies.
This study may require blood draws, lung function tests, nutritional assessments, and/or other measurements.
Email a research coordinator to express interest in participating in this study.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
No FEV1 Limit
For a more comprehensive list of eligibility criteria and details on this study, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
The participants for Cohort 1 must have an FEV1 of 60% or lower at the screening visit. The participants for Cohort 2 must have an FEV1 of 60% or greater at the screening visit.
Study Design
-
Study Type: ?more info
Observational -
Randomized Study: ?more info
No -
Placebo Controlled: ?more info
No -
Length of Participation:
12 months -
Number of Study Visits:
5
Additional Information
-
Phase: ?more info
Not Applicable -
Study Sponsor: ?more info
-
Study Drugs:
N/A
Study Sites
-
Enrolling
Arizona
Tucson Cystic Fibrosis Center, Tucson, AZ 85719
Contact
Elizabeth Ryan
Phone: +1 (520) 850-8688
Email: elizabethryan@arizona.edu
-
Enrolling
Arkansas
University of Arkansas for Medical Sciences, Little Rock, AR 72205
Contact
Kathleen Hicks
Phone: +1 (501) 686-5527
Email: HicksKathleenT@uams.edu
-
Enrolling
Georgia
Emory University, Atlanta, GA 30324
Contact
Ashleigh Streby
Phone: +1 (404) 727-0305
Email: ashleigh.streby@emory.edu
-
Enrolling
Illinois
Northwestern University, Chicago, IL 60611
Contact
Rachel Nelson
Phone: +1 (312) 695-0415
Email: rachel.nelson@northwestern.edu
-
Enrolling
Iowa
University of Iowa, Iowa City, IA 52242
Contact
Mary Teresi
Phone: +1 (319) 384-7546
Email: mary-teresi@uiowa.edu
-
Enrolling
Kentucky
University of Kentucky, Lexington, KY 40536
Contact
Chase Whitaker
Phone: +1 (859) 218-4810
Email: chase.whitaker@uky.edu
-
Closed to Enrollment
Louisiana
Tulane University, Metairie, LA 70006
-
Enrolling
Maryland
Johns Hopkins University, Baltimore, MD 21205
Contact
Jeanne Pinto
Phone: +1 (410) 955-9782
Email: jpinto4@jh.edu
-
Enrolling
Massachusetts
Boston Children's Hospital, Boston, MA 02115
Contact
Robert Fowler
Phone: +1 (617) 355-1834
Email: Robert.fowler@childrens.harvard.edu
-
Enrolling
Massachusetts
Massachusetts General Hospital, Boston, MA 02114
Contact
Margot Hardcastle
Phone: +1 (617) 726-3719
Email: mhardcastle@mgh.harvard.edu
-
Enrolling
Minnesota
The Minnesota Cystic Fibrosis Center, Minneapolis, MN 55455
Contact
Participant Contact University of Minnesota
Phone: +1
Email: cftrials@umn.edu
-
Enrolling
Missouri
Washington University School of Medicine, St. Louis, MO 63110
Contact
Irma Bauer
Phone: +1 (314) 747-2940
Email: irmabauer@wustl.edu
-
Closed to Enrollment
New Jersey
Rutgers - Robert Wood Johnson Medical School, New Brunswick, NJ 08903
-
Enrolling
New York
Long Island Jewish Medical Center, New Hyde Park, NY 11042
Contact
Cara Fidnarick
Phone: +1 (516) 465-5400
Email: cfidnari@northwell.edu
-
Enrolling
New York
New York Medical College at Westchester Medical Center, Valhalla, NY 10595
Contact
Zachary Messer
Phone: +1 (914) 594-2352
Email: Zachary_Messer@nymc.edu
-
Enrolling
Ohio
University of Cincinnati Medical Center, Cincinnati, OH 45267
Contact
Nicole Hummel
Phone: +1 (513) 558-7036
Email: hummelne@ucmail.uc.edu
-
Enrolling
Ohio
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland, OH 44106
Contact
Primary RC & Participant Contact General Contact
Phone: +1
Email: RainbowCFResearch@UHhospitals.org
-
Enrolling
Oklahoma
Oklahoma Cystic Fibrosis Center, OKC, OK 73104
Contact
Participant Contact Oklahoma Cystic Fibrosis Center
Phone: +1 (405) 271-6216
Email: cfresearchteam@ouhsc.edu
-
Enrolling
Oregon
Oregon Health Sciences University, Portland, OR 97239
Contact
Jenna Bucher
Phone: +1 (503) 494-7807
Email: bucherj@ohsu.edu
-
Enrolling
Pennsylvania
University of Pittsburgh Medical Center, Pittsburgh, PA 15224
Contact
Elizabeth Hartigan
Phone: +1 (412) 692-7060
Email: elizabeth.hartigan@chp.edu
-
Enrolling
South Carolina
Medical University of South Carolina, Charleston, SC 29425
Contact
Ashley Warden
Phone: +1 (843) 792-4349
Email: jonesash@musc.edu
-
Enrolling Soon
Texas
Baylor College of Medicine, Houston, TX 77030
Contact
Tracy Mosely
Phone: +1 (832) 822-3309
Email: tlmosely@texaschildrens.org
-
Enrolling
Virginia
University of Virginia, Charlottesville, VA 22908
Contact
Erica Tharrington
Phone: +1 (434) 297-7773
Email: SFV6AB@hscmail.mcc.virginia.edu
Email a research coordinator to express interest in participating in this study.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
No FEV1 Limit
For a more comprehensive list of eligibility criteria and details on this study, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
The participants for Cohort 1 must have an FEV1 of 60% or lower at the screening visit. The participants for Cohort 2 must have an FEV1 of 60% or greater at the screening visit.
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More